新的治疗模式:初级IgA脏病
Haresh Selvaskandan1,2, Jonathan Barratt1,2, Chee Kay Cheung1,2
1Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Kidney international reports
|February 12, 2024
概括
治疗IgA病 (IgAN) 正在发展,新的疗法针对其原因. 最近的批准为患有功能衰竭的患者提供了希望,标志着管理这种常见病的进展.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在全球范围内,IgA神经病变 (IgAN) 是最常见的原发性血球蛋白质神经炎.
- 很大一部分IGAN患者在20-25年内患上功能衰竭 (KF),而历史上有效治疗方法有限.
- 对Igan缺乏有效的治疗方法,造成了严重的未满足需求.
研究的目的:
- 审查目前的,最近批准的,以及IgA病的新兴治疗策略.
- 突出了解IGAN病理生理学的进步,推动新的治疗开发.
- 讨论替代终点 (如蛋白尿减少) 对加速药物批准的影响.
主要方法:
- 关于IgA脏病病理生理学和治疗学的当前文献的综述.
- 对Igan最近批准的药物的分析.
- 讨论临床开发中的新兴治疗点和药物.
主要成果:
- 两个药物,向释放配方 (TRF) - 布德索尼德 (nefecon) 和sparsentan,已经获得基于减少蛋白尿的加速批准.
- 新的疗法正在出现,这些疗法针对关键的病理生理路径,包括粘膜免疫,B细胞,补充体和内甲蛋白系统.
- 对Igan的治疗环境正在迅速变化,出现了新的治疗选择.
结论:
- 最近的治疗进展和批准代表了在治疗IgA病的管理方面取得的重大进展.
- 了解Igan复杂的病理生理学对于开发有针对性和有效的治疗方法至关重要.
- 不断变化的治疗环境为Igan患者提供了更好的前景,可能会改变导致功能衰竭的过程.
相关概念视频
01:27Open Angle Glaucoma: Treatment
449
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
449
01:25Antihypertensive Drugs: Direct Renin Inhibitors
629
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
629
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
164
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
164